bispecific antibodies

04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
2:25
Analyzing AML: novel therapies in review
Farhad Ravandi
2:19
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon
1:40
Antibodies for AML: updates from ASH
Marina Konopleva
1:21
An update on the state-of-affairs of BiTEs in the world of AML
Marion Subklewe
1:57
An update on AMG-330: can BiTEs be as successful in AML as ALL?
Marion Subklewe
1:21
Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL
Ian Flinn
2:03
Bispecific antibody response boosting with ibrutinib for CLL
Adrian Wiestner
1:23
Targeting BCMA with bispecific antibodies in R/R myeloma
Saad Usmani
1:32
Immunotherapeutics against multiple myeloma: it’s all about BCMA
Enrique Ocio
1:35
Monoclonal antibodies: current and future potential
Saad Usmani
2:45
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
Heinz Ludwig
1:09
Non-hodgkin lymphoma advances in 2018
Steven Rosen
3:29
Novel drugs and targets in MDS
Valeria Santini
6:20
Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
Florian Bassermann et al.
2:41
Immunotherapy in AML: azacitidine plus checkpoint inhibitors
Naval Daver
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals